Moxifloxacin (Avelox 400 mg) and Nilotinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Additive QT prolongation may increase serious ventricular arrhythmia risk.
Clinical significance and safety
Avelox 400 mg is a QT-prolonging medicine. TASIGNA advises avoiding other QT-prolonging agents because of potentially dangerous ventricular arrhythmias. The prescribing team should review alternatives, ECGs and electrolytes. Fainting or new palpitations need prompt assessment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.